Picture of ALX Oncology Holdings logo

ALXO — ALX Oncology Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

ALX Oncology Holdings Inc expected to post a loss of 45 cents a share - Earnings Preview

ALX Oncology Holdings Inc ALXO.OQ ALXO.O is expected to  show no change in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for ALX Oncology Holdings Inc is for a loss of 45 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for ALX Oncology Holdings Inc is $2.50, about 79.3% above its last closing price of $0.52

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATEACTUALBEAT, MET, MISSEDSURPRISE %
Mar. 31 2025-0.45-0.46-0.58Missed-25
Dec. 31 2025-0.62-0.67-0.55Beat17.9
Sep. 30 2024-0.78-0.78-0.58Beat25.6​
Jun. 30 2024-0.77-0.77-0.76Beat1.7
​​Mar. 31 2024-0.85-0.84-0.71Beat15.1
Dec. 31 2023-0.81-0.84-0.93Missed-10.5​
Sep. 30 2023-0.82-0.87-1.24Missed-42.5
Jun. 30 2023-0.88-0.88-0.84Beat4.5
This summary was machine generated August 4 at 20:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on ALX Oncology Holdings

See all news